Zanubrutinib Combination With R-CHOP in Treating Patients With Newly Diagnosed Untreated Non-GCB DLBCL
Latest Information Update: 19 Sep 2022
At a glance
- Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Vincristine (Primary) ; Zanubrutinib (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 14 Sep 2022 Planned number of patients changed from 20 to 78.
- 14 Sep 2022 Planned End Date changed from 1 Oct 2024 to 1 Oct 2025.
- 14 Sep 2022 Planned primary completion date changed from 1 Oct 2024 to 1 Oct 2025.